COVID-19 Phase 1 trial results show Covaxin has tolerable safety, enhanced immunity: Lancet study ...United Arab Emirates

Gulf News - News
COVID-19 Phase 1 trial results show Covaxin has tolerable safety, enhanced immunity: Lancet study
New Delhi: India's first indigenous vaccine against COVID-19, Covaxin, showed enhanced immune response without any serious side effects in the participants enrolled for the phase 1 trials, according to the results published in The Lancet Infectious Disease journal. Developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV), Pune, the vaccine has been granted emergency use authorisation in clinical trial mode' by the Indian government. Covaxin, which is now undergoing phase-3 trials, had raised concerns among experts over its emergency approval earlier this month by India's drug regulator. The vaccine, codename

Hence then, the article about covid 19 phase 1 trial results show covaxin has tolerable safety enhanced immunity lancet study was published today ( ) and is available on Gulf News ( United Arab Emirates ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( COVID-19 Phase 1 trial results show Covaxin has tolerable safety, enhanced immunity: Lancet study )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News